Recruiting Atrial Fibrillation Studies in Los Angeles
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation ...
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet t...
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery
Multinational, investigator-initiated study of oral anticoagulation versus no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient perioperat...
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their respon...
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in par...
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the second...
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in...
About Atrial Fibrillation Clinical Trials in Los Angeles
Atrial fibrillation (AFib) is the most common type of heart arrhythmia, causing an irregular and often rapid heartbeat. It significantly increases the risk of stroke, heart failure, and other complications. Treatment includes blood thinners, heart rate or rhythm control medications, and procedures like ablation.
There are currently 7 atrial fibrillation clinical trials recruiting participants in Los Angeles, CALIFORNIA. These studies are seeking a combined 12,942 participants. Research is being sponsored by Johns Hopkins University, Icahn School of Medicine at Mount Sinai, Population Health Research Institute and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Atrial Fibrillation Clinical Trials in Los Angeles — FAQ
Are there atrial fibrillation clinical trials in Los Angeles?
Yes, there are 7 atrial fibrillation clinical trials currently recruiting in Los Angeles, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Los Angeles?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Los Angeles research site will contact you about next steps.
Are clinical trials in Los Angeles free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Los Angeles studies also compensate for your time and travel.
What atrial fibrillation treatments are being tested?
The 7 active trials in Los Angeles are testing new therapies including novel drugs, biologics, and treatment approaches for atrial fibrillation.
Data updated March 2, 2026 from ClinicalTrials.gov